Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis

British Medical Journal

Volumn 323, Issue 7305, 2001, Pages 131-134

  Kemmeren, J M ^a   Algra, A ^a   Grobbee, D E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DESOGESTREL; GESTODENE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0035928499     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.323.7305.131     Document Type: Article

References (28)

1. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study
2. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
3. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
4. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study
5. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
6. First-time use of newer oral contraceptives and the risk of venous thromboembolism
7. Oral contraceptives and venous thromboembolism. A case-control study
8. The aftermath of a pill scare: Regression to reassurance
9. Cardiovascular disease and combined oral contraceptives: Reviewing the evidence and balancing the risks
10. Statistical methods in meta-analysis
11. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias
12. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
13. The risks of venous thromboembolic disease among German women using oral contraceptives: A database study
14. Venous thromboembolism among new users of different oral contraceptives
15. The differential risk of oral contraceptives: The impact of full exposure history
16. Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies
17. Venous thromboembolic disease and combined oral contraceptives: A reanalysis of the MediPlus database
18. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives
19. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: Cohort and case-control analysis
20. The risk of venous thromboembolism in users of postcoital contraceptive pills
21. The hazards of scoring the quality of clinical trials for meta-analysis
22. Scoring the quality of clinical trials
23. Study on risks of third generation pill "kept secret by industry."
24. Third-generation oral contraceptive and deep venous thrombosis: From epidemiologic controversy to new insight in coagulation
25. Newer oral contraceptives and the risk of venous thromboembolism
26. Conflict of interest in the debate over calcium-channel antagonists
27. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis
28. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General Practice Research Database and the UK Mediplus database